![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MAB21L3 |
Gene summary for MAB21L3 |
![]() |
Gene information | Species | Human | Gene symbol | MAB21L3 | Gene ID | 126868 |
Gene name | mab-21 like 3 | |
Gene Alias | C1orf161 | |
Cytomap | 1p13.1 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q8N8X9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
126868 | MAB21L3 | HCC1 | Human | Liver | HCC | 5.57e-49 | 5.49e+00 | 0.5336 |
126868 | MAB21L3 | HCC2 | Human | Liver | HCC | 7.16e-83 | 6.87e+00 | 0.5341 |
126868 | MAB21L3 | HCC5 | Human | Liver | HCC | 1.37e-29 | 3.91e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAB21L3 | SNV | Missense_Mutation | c.789G>C | p.Met263Ile | p.M263I | Q8N8X9 | protein_coding | tolerated(0.1) | benign(0.023) | TCGA-D8-A1JC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
MAB21L3 | SNV | Missense_Mutation | novel | c.826N>T | p.Arg276Trp | p.R276W | Q8N8X9 | protein_coding | deleterious(0) | possibly_damaging(0.858) | TCGA-E2-A1LS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cyclophosphamide | SD |
MAB21L3 | SNV | Missense_Mutation | c.956N>C | p.Val319Ala | p.V319A | Q8N8X9 | protein_coding | tolerated(0.05) | benign(0.373) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
MAB21L3 | SNV | Missense_Mutation | novel | c.467N>T | p.Thr156Ile | p.T156I | Q8N8X9 | protein_coding | deleterious(0.02) | possibly_damaging(0.713) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAB21L3 | SNV | Missense_Mutation | c.683N>G | p.Ala228Gly | p.A228G | Q8N8X9 | protein_coding | deleterious(0.01) | benign(0.343) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
MAB21L3 | SNV | Missense_Mutation | rs760066154 | c.1082N>T | p.Pro361Leu | p.P361L | Q8N8X9 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
MAB21L3 | SNV | Missense_Mutation | novel | c.87N>T | p.Glu29Asp | p.E29D | Q8N8X9 | protein_coding | tolerated(0.16) | benign(0.017) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAB21L3 | SNV | Missense_Mutation | novel | c.580N>T | p.Pro194Ser | p.P194S | Q8N8X9 | protein_coding | tolerated(0.11) | probably_damaging(0.961) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAB21L3 | SNV | Missense_Mutation | c.325N>T | p.Gly109Cys | p.G109C | Q8N8X9 | protein_coding | deleterious(0.01) | possibly_damaging(0.754) | TCGA-AX-A06H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD | |
MAB21L3 | SNV | Missense_Mutation | c.653N>A | p.Cys218Tyr | p.C218Y | Q8N8X9 | protein_coding | tolerated(0.08) | probably_damaging(0.998) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |